System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT05531773 on ClinicalTrials.gov

Post COVID-19 Condition

Official title: Assessment of Post COVID-19 Manifestations in a Multicenter Cohort Study (EuCARE-POSTCOVID Study)

  • Sponsor: Euresist Network GEIE
  • Collaborators: ASST Santi Paolo e Carlo, Vilnius University Hospital Santaros Klinikos, Heinrich-Heine University, Duesseldorf, University of Rome Tor Vergata, Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus", St Mary's Hospital, London, Centro Hospitalar Lisboa Ocidental
  • Enrollment: 2300 (Estimated)
  • Study start: 2022-07-01 (Actual)
  • Primary completion: 2025-12-15 (Estimated)
  • Study completion: 2025-12-15 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

The EuCARE-POSTCOVID study is an observational multicentre study enrolling COVID-19 patients recovered from the acute phase of disease to investigate the prevalence and possible predictors of post COVID-19 condition. The study will retrospectively analyze data already collected at the post COVID-19 outpatients services of the participating centers; furthermore, a prospective cohort study will be performed.

Conditions

  • COVID-19

Intervention / Treatment

  • Other: follow up of COVID-19 Patients

Primary Outcome Measures

  • Overall incidence of post COVID-19 condition (through study completion, an average of 3 years)
  • Persistence of post COVID-19 condition beyond 2-3 months from the acute COVID-19 disease (through study completion, an average of 3 years)
  • Predictors of post COVID-19 condition (through study completion, an average of 3 years)
  • Long-term organ damage (lung, heart, Central Nervous System, Peripheral Nervous System) associated with post COVID-19 condition (through study completion, an average of 3 years)
  • Virological and immunological phenotype of post COVID-19 condition (through study completion, an average of 3 years)

Countries

Germany, Italy, Lithuania, Mexico, Portugal, United Kingdom

Locations and Investigators

  • University Hospital Heinrich Heine, Düsseldorf, Germany (Recruiting)
    • BJOERN JENSEN
  • Policlinico "Tor Vergata", Università degli Studi di Roma TOR VERGATA, Rome, Italy (Recruiting)
    • FRANCESCA CECCHERINI SILBERSTEIN, PROF
  • ASST Santi Paolo e Carlo, Milan, Italy (Recruiting)
    • ANTONELLA D'ARMINIO MONFORTE, PROF
  • Vilnius University Hospital, Santaros Klinikos, Vilnius, Lithuania (Recruiting)
    • DANIEL NAUMOVAS, DR
  • Regional Hospital Dr. Juan Graham Casasús, Villahermosa, Mexico (Recruiting)
    • Gibran Rubio Quintanares, DR
  • Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal (Recruiting)
    • CRISTINA TOSCANO, DR
  • St. Mary Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom (Recruiting)
    • FRANCIS Drobniewski, PROF

Study Officials

  • ANTONELLA D'ARMINIO MONFORTE, PROF (Study Chair) — ASST SANTI GIOVANNI E CARLO